SCHEMBL10101187

SCHEMBL10101187

CC1(C)CCC[C@]2(C)[C@H]3CS(=O)(=O)c4cc(OCC(=O)O)cc(OCC(=O)O)c4[C@]3(C)CC[C@@H]12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 1/20 0.41
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
TSHR P16473 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HIF1A Q16665 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
BLM P54132 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PTGDR2 Q9Y5Y4 8/20 0.34
PTGDR Q13258 4/20 0.34
MAPKAPK2 P49137 1/20 0.33
PLA2G2A P14555 2/20 0.32
PTPN2 P17706 2/20 0.31
PTPN1 P18031 2/20 0.31
TRPM2 O94759 1/20 0.31
TRPV1 Q8NER1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10101389 0.96 PIK3CB (0.38) PIK3CBCYP3A4CYP2C9TSHRALDH1A1
SCHEMBL10101184 0.94 PIK3CB (0.39) PIK3CBCYP3A4CYP2C9TSHRALDH1A1
SCHEMBL10101185 0.91 PIK3CB (0.45) PIK3CBCYP3A4CYP2C9TSHRALDH1A1
SCHEMBL10101288 0.86 PIK3CB (0.37) PIK3CBTSHRALDH1A1MEN1KMT2A
SCHEMBL10101126 0.81 PIK3CB (0.39) PIK3CBCYP3A4CYP2C9TSHRALDH1A1
SCHEMBL10101188 0.81 FKBP1A (0.41) ALDH1A1HSD17B10KDM4E
SCHEMBL10101383 0.78 PIK3CB (0.39) PIK3CBMAPKAPK2PLA2G2APTPN2PTPN1
SCHEMBL10101164 0.78 PIK3CB (0.45) PIK3CBCYP3A4CYP2C9TSHRALDH1A1
SCHEMBL10101274 0.77 PIK3CB (0.37) PIK3CBCYP3A4CYP2C9TSHRALDH1A1
SCHEMBL10101153 0.76 PIK3CB (0.42) PIK3CBCYP3A4CYP2C9TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101605-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPM1D, PTPRO, PPM1G PIK3CB 98/4885CYP3A4 4358/4885CYP2C9 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.